Summary:
Click image to enlarge
Treatments like statins and other existing medicines help people manage their LDL cholesterol levels. However, for some people, these treatments do not lower LDL cholesterol levels enough and they remain at higher risk.
A group of treatments, called PCSK9 inhibitors, are known to help reduce LDL cholesterol levels. However, these are currently all given as injections, which we know may not be convenient for some people. New, easy and convenient treatment options are needed to support those living with ASCVD or at risk for ASCVD-related events.
This study is looking at an oral PCSK9 inhibitor called AZD0780. We want to find out whether it may help to reduce LDL cholesterol levels and the risk of cardiovascular-related events or medical procedures. By taking part in this study, you’re helping us look for new ways to improve care and outcomes for people like you.
Qualified Participants Must:
• Age 45 or older
•
Body Mass Index (BMI) greater than 27 kg/m2
•
One of the following:- Male over 50 or Female over 55 AND high LDL Cholesterol (greater than 100 mg/dL)
- Have acute coronary syndrome (unstable angina or heart attack) in the last 1-12 months
- Ischaemic stroke in the last 1-12 months
- Revascularization of lower limb due to PAD
*Please note: additional conditions may be required for eligibility
Qualified Participants May Receive:
For this study, you'll receive $125 per completed visit, including unscheduled visit (plus additional compensation for optional assessments).
Up to $1,500 for eligible participants who complete the study